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Peroxisomeproliferator-activatedreceptors(PPARs)belongtothenuclearreceptorfamilyofligand-activatedtranscriptionfactors.
This subfamily is composed of three members—PPARα,P P A R δ,a n dP P A R γ—that diﬀer in their cell and tissue distribution as
well as in their target genes. PPARα is abundantly expressed in liver, brown adipose tissue, kidney, intestine, heart, and skeletal
muscle; and its ligands have been used to treat diseases such as obesity and diabetes. The recent ﬁnding that members of the
PPAR family, including the PPARα, are expressed by tumor and endothelial cells together with the observation that PPAR ligands
regulate cell growth, survival, migration, and invasion, suggested that PPARs also play a role in cancer. In this review, we focus on
the contribution of PPARα to tumor and endothelial cell functions and provide compelling evidence that PPARα can be viewed
as a new class of ligand activated tumor “suppressor” gene with antiangiogenic and antitumorigenic activities. Given that PPAR
ligands are currently used in medicine as hypolipidemic drugs with excellent tolerance and limited toxicity, PPARα activation
might oﬀer a novel and potentially low-toxic approach for the treatment of tumor-associated angiogenesis and cancer.
Copyright © 2008 A. Pozzi and Jorge H. Capdevila. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. THE PEROXISOMAL PROLIFERATOR-ACTIVATED
RECEPTORS (PPARs)
PPARs nuclear receptors that regulate many physiological
processes, including lipid and glucose homeostasis, inﬂam-
mation, and wound healing [1]. Three PPAR isotypes have
been identiﬁed: α, δ (or β), and γ. Upon ligand binding,
PPARs form heterodimers with the retinoic acid receptor
and interact with speciﬁc response elements in the promoter
region of target genes [2]. Although PPARs share extensive
structural homology, each isotype appears to possess distinct
functions.PPARγ isexpressedmainlyinadiposetissueandat
lower levels in intestine and immune cells [3–5]. It controls
adipocyte diﬀerentiation, glucose and lipid homeostasis [5–
7] and has been implicated in the pathophysiology of
insulin resistance and atherosclerosis [1, 8]. PPARγ ligands
include long-chain fatty acids, prostaglandins, and other
eicosanoids [4]. Among the synthetic PPARγ ligands, the
thiazolidinediones are currently used as insulin sensitizers
in patients with type-2 diabetes [9]. PPARδ is ubiquitously
expressed and it is most abundant in brain, colon, and
skin [10, 11], and binds molecules such as fatty acids and
prostaglandins [4].
PPARα is primarily expressed in liver, brown adipose
tissue, kidney, intestine, heart, and skeletal muscle. This
receptor controls fatty acid metabolism and transport, per-
oxisomal and mitochondrial β-oxidation [3, 4]. Moreover,
this receptor has been implicated in the pathophysiology
of inﬂammation and cardiovascular diseases [12]. Several
compounds bind PPARα, including fatty and phytanic acids
[4], as well as the ﬁbric acid derivatives used in medicine for
the treatment of hyperlipidemias [1].
2. PPARs AND CANCER
The observation that members of the PPAR family are
expressed by tumor and endothelial cells [13, 14] together
with the ﬁnding that PPAR ligands regulate cell growth,
survival, migration, and invasion [15, 16]p r o m p t e di n v e s t i -
gators to determine whether these receptors play a role in the
pathophysiology of tumorigenesis and angiogenesis [17, 18].
The anticancer eﬀects of PPARγ agonists have been
extensively studied because of their antiproliferative, proap-
optotic, antiapoptotic, and diﬀerentiation-promoting activ-
ities [19]. In this context, activation of PPARγ has been2 PPAR Research
reported to reduce tumor cell proliferation and invasion [20]
and to enhance apoptosis [21]. PPARγ ligands also regulate
endothelial cell growth, migration, and angiogenesis [22–
25], and inﬂuence the progression of vascular inﬂammation
and tumorigenesis [26, 27]. Moreover, disruption of the
PPARγ gene in the intestine enhances tumorigenesis in
ApcMin/+ mice [28]. Although these studies suggest that
PPARγ functions as a tumor suppressor factor and its
activation might be beneﬁcial for patients with tumors,
PPARγ agonists have been shown also to increase the
frequency of colon tumors [29] and to promote edema [30].
In contrast to PPARγ,P P A R δ has been described as
protumorigenic as its ligand-mediated activation increases
tumor-associated angiogenesis [31]. Moreover, treatment of
ApcMin/+ mice with PPARδ antagonists or crossing these
mice with PPARδ-null mice prevents tumor growth and
angiogenesis [31]. However, a recent study showed that
activation of this receptor attenuates chemically-induced
colon carcinogenesis, and that PPARδ-null mice exhibit
increased colon polyp multiplicity, suggesting that ligand
activation of this receptor can also inhibit carcinogenesis
[32].
The analysis of the antitumorigenic properties of PPARα
ligands has been less studied mostly due to the observation
that long-term administration of certain PPARα agonists
(Cloﬁbrateand WY14643) induces hepatocarcinogenesis in
rodents [33–35], despite the fact that PPARα ligands are
widelyusedinmedicineasantilipidemicdrugswithexcellent
tolerance and little or no reported side eﬀects. The ﬁnding
that fenoﬁbrate decreases VEGF levels in patients with
hyperlipidemiaand atherosclerosis [36]p r o v i d e dar a t i o n a l e
for analyzing PPARα and its ligands as a molecular target for
cancer therapy. In this review, we highlight some of the key
functions attributed to PPARα in the context of endothelial
and tumor cell biology.
3. PPARα TARGETS IN ANGIOGENESIS
PPARα controls the transcription of many genes involved in
cell functions such as lipid metabolisms, inﬂammation, cell
cycle progression, and angiogenesis. Among the angiogenic
targets, PPARα has been shown to regulate the expression
of the vascular endothelial growth factor (VEGF), ﬁbroblast
growth factors (FGFs), members of the arachidonic acid
P450 monooxygenases, thrombospondin and endostatin to
name few (see also Figure 1 and Table 1). Biscetti et al. have
recently shown that the selective PPARα agonist WY14643
promotescorneaangiogenesisinvivoandenhancesendothe-
lial tubulogenesis in vitro [37]. Interestingly, WY14643 can
enhance endothelial cell tubulogenesis in vitro only when
endothelial cells are cocultured with interstitial cells and this
eﬀect is accompanied by upregulation of interstitial-derived
VEGF synthesis [37]. However, WY14643 does not directly
promote endothelial cell migration or proliferation, and
when used at 10–20μM range it reduces both endothelial cell
proliferation and migration [37]. Thus, this study indicates
that while WY14643 might directly prevent endothelial cell
functions, it might also promote angiogenesis by stimulating
the production of nonendothelial VEGF. The observation
that activation of PPARα prevents endothelial cell pro-
liferation/migration parallels our ﬁndings that WY14643
prevents—in a PPARα-dependent fashion—endothelial cell
proliferation in vitro and tumorigenesis in vivo [38].
The antiangiogenic properties of WY14643 are associated
with a PPARα-dependent downregulation of the epoxy-
genase branch of the cytochrome P450 arachidonic acid
monooxygenases [38]. The arachidonic acid epoxygenases
are expressed by endothelial cells both in vitro and in vivo
[39–41] and catalyze the oxidation of arachidonic acid to
four regioisomeric epoxyeicosatrienoic acids (EETs) [42, 43].
EETs have been shown to possess proangiogenic activities
[39, 44–47] and we have demonstrated that WY14643-
mediated PPARα activation directly prevents endothelial cell
migration and proliferation by downregulating endothelial
arachidonate epoxygenase expression and EET biosynthesis
[38]. Most importantly, in vivo treatment with WY14643
prevents primary tumor growth and tumor-associated
angiogenesisbydownregulatingthelevelsofcirculatingEETs
[38].
Consistent with the observation that PPARα ligands
might act as potent direct and/or indirect antiangiogenic
factors, Panigrahy et al. have recently shown that fenoﬁbrate
suppresses VEGF-mediated endothelial cell proliferation as
well as tumor cell-derived VEGF and FGF2 synthesis with
concomitant stimulation of tumor-cells derived throm-
bospondin and endostatin [48]. Moreover, fenoﬁbrate and
WY14643 prevent VEGF-mediated endothelial cell migra-
tion by inhibiting Akt phosphorylation [24] and fenoﬁ-
brate prevents endothelial cell proliferation by inhibiting
cyclooxygenase-2 expression [25]. Finally, PPARα agonists
were found to inhibit endothelial VEGFR2 expression by
preventing Sp1-dependent promoter binding and transac-
tivation [23]. Some of the major PPARα targets known to
control endothelial cell functions and the eﬀects of PPARα
ligands on angiogenesis are summarized in Figure 1 and
Table 1.
In conclusion these studies strongly suggest that by pre-
ventingendothelialcellfunctionsPPARαligandsmayprotect
the vasculature from pathological alterations associated with
either metabolic disorders (i.e., atherosclerosis, diabetes)
or cancer. Thus, PPARα can be considered as a new class
of “antiangiogenic” gene, and suggest that its ligands may
function as eﬀective antiangiogenic drugs.
4. PPARα TARGETS IN CANCER
The observation that PPARα is expressed by tumor cells
[59–61] started studies of the role of this nuclear receptor
and its ligands on the prevention of tumor cell proliferation
in vitro and in vivo. In this context it has been shown
that PPARα ligands suppress the growth of several can-
cer lines—including colon, liver, breast, endometrial, and
skin—in vitro [62–66], as we all inhibit the metastatic
potential of melanoma cells in vitro and in vivo [67, 68].
Furthermore, PPARα ligands decrease colon carcinogenesis
[62] and the growth of human ovarian cancer in mice
[49]. Although the mechanisms whereby PPARα directly
prevents tumor cell functions have not been investigatedA. Pozzi and Jorge H. Capdevila 3
Table 1: Eﬀect of PPARα activation on angiogenesis and tumorigenesis.
Ligand Cell type Eﬀect Target Reference
WY14643 Endothelial cells
Inhibition of cell
proliferation and
tubulogenesis in vitro
Antiangiogenic activity
in vivo
Downregulation of arachidonate
epoxygenase synthesis
[38]
WY14643 Endothelial cells
Enhanced endothelial
t u b ef o r m a t i o ni nv i t r o
Proangiogenic activity in
vivo
Upregulation of VEGF production [37]
Fenoﬁbrate
WY14643
ETYA
Endothelial cells
Inhibition of VEGF- or
FGF2-mediated cell
proliferation in vitro
Antiangiogenic activity
in vivo
Downregulation of VEGF production
Upregulation of thrombospondin
and endostatin production
[48]
Fenoﬁbrate
WY14643 Endothelial cells Reduced cell migration Inhibition of Akt activation [24]
Fenoﬁbrate Endothelial cells Reduced cell
proliferation
Inhibition of cyclooxygenase-2
expression
[25]
Fenoﬁbrate Endothelial cells Reduced cell
proliferation Inhibition of VEGFR2 expression [23]
Cloﬁbrate Ovarian cancer
cells
Reduced cell
proliferation in vitro
Antitumorigenic activity
in vivo
Reduced prostanoid and VEGF levels
via upregulation of carbonyl
reductase expression
[49]
Methylclofenapate Colonic
adenocarcinoma
Reduced cell
proliferation Not investigated [50]
Methylclofenapate Apc
Min/+ mice Reduced number of
intestinal polyps Not investigated [50]
Bezaﬁbrate APC1309mice
Apc
Min/+ mice
Reduced number of
intestinal polyps
Reduced serum level of triglycerides
and increased lipoprotein lipase
synthesis
[27, 51]
WY14643 Wild-type mice
Enhanced hepatocellular
proliferation and
tumorigenesis in vivo
Downregulation of the miRNA
let-7C with increased c-myc
expression
[52]
Thrombospondin synthesis
Endostatin generation
VEGF synthesis
Carbonyl reductase
Serum triglycerides
Lipoprotein lipase synthesis
Tumor suppressor p16INK4a
P450 arachidonate epoxygenase-derived EETs
Cyclooxygenase-2 expression
VEGFR2 expression
VEGF-mediated Akt activation
VEGF- or FGF2-mediated proliferation and migration
Direct PPARα ligand-mediated anti-angiogenic functions
Direct PPARα ligand-mediated anti-tumorigenic functions
Indirect PPARα ligand-mediated anti-angiogenic functions
Figure 1: Schematic representation of the antiangiogenic and antitumorigenic properties of PPARα.P P A R α ligands reduce tumor growth by
direct inhibition of tumor cell functions (black pathway). In addition, they prevent tumor-associated angiogenesis via direct (red pathway)
as well as indirect (green pathway) inhibition of endothelial cell functions.4 PPAR Research
Table 2: PPARα and tumorigenesis: lessons from the PPARα-null mice.
Ligand Host Challenge Eﬀect Target Reference
WY14643 PPARα-null mice
Resistant to the
development of
spontaneous
hepatocarcinoma
Inability to downregulate the
miRNA let-7C
[52]
WY14643
Fenoﬁbrate
PPARα-humanized
transgenic mouse
Resistant to the
development of
spontaneous
hepatocarcinoma
Inability to downregulate the
microRNA let-7C
[53, 54]
WY14643 PPARα-null mice
Injection of
isogenic tumor
cells
Resistant to the
Wyeth-mediated
antiangiogenic and
antitumorigenic
activities
Inability to downregulate
arachidonate epoxygenase
expression
[38]
DEHP PPARα-null mice Development of
hepatocarcinoma
Increased PPARα-independent
oxidative stress
[55]
WY14643
Fenoﬁbrate PPARα-null mice Carotid arterial
injury Intimal hyperplasia
Inability to induce the
expression of the tumor
suppressor p16INK4a
[56]
PPARα-null mice
Injection of
isogenic tumor
cells
Resistant to the
development of
primary and
metastatic tumor
growth
Increased recruitment of
granulocyte responsible for
thrombospondin production
[57]
PPARα-null mice
Increased
susceptibility to
spontaneous
adenomas and
hepatocellular
carcinomas
Not explored [58]
in details, potential targets have been identiﬁed. Cloﬁbrate,
aP P A R α ligand, signiﬁcantly suppressed the growth of
OVCAR-3 xenotransplanted tumors and inhibited ovarian
tumor cell proliferation by increasing the expression of
carbonyl reductase, an enzyme that promotes the conversion
of protumorigenic prostaglandin E2 to inactive PGF2α [49].
Moreover, cloﬁbrate reduced the levels of circulating VEGF
in tumor-bearing mice [49], while bezaﬁbrate, another
PPARα ligand, decreased the number of intestinal polyps
in ApcMin/+ mice possibly by lowering serum level of
triglycerides and upregulating lipoprotein lipase synthesis
[27, 51]. Finally, PPARα activation has been shown to
inhibit vascular smooth muscle cell proliferation underlying
intimal hyperplasia by inducing the expression of the tumor
suppressor p16INK4a [56].
Whereas these studies clearly suggest that PPARα activa-
tion might be beneﬁcial in reducing cancer growth, studies
from the Gonzales laboratory demonstrate that long-term
administration of certain PPARα agonists (cloﬁbrate and
WY14643) induces liver adenoma and carcinomas in rats
and mice [35, 52, 69, 70]. The ability of PPARα ligands to
induce hepatocarcinoma is PPARα-dependent and mediated
by the novel microRNA let-7C/c-myc axis [52]. Let-7C is
a micro RNA that controls cell growth by directly down-
regulating c-myc expression [52]. Upon treatment of mice
with WY14643, the hepatic expression of let-7C decreases
with the concomitant induction of c-myc and the increased
expression of the oncogenic mir-17-92 cluster [52]. Thus,
this novel rodent speciﬁc PPARα-regulated pathway might
be responsible for increased hepatocellular proliferation and
tumorigenesis.
All together, these ﬁndings indicate that, with few
exceptions, PPARα ligands can be viewed as antitumorigenic
agents either by directly preventing tumor cell functions or
by preventing tumor-derived production of proangiogenic
molecules. Some of the potential PPARα targets that control
tumor cell functions and the eﬀects of PPARα ligands on
tumorigenesis are summarized in Figure 1 and Table 1.
5. PPARα LIGANDS AND TUMORIGENESIS:
LESSONS FROM MICE
ThegenerationofPPARαnullmicehasprovidedanexcellent
tool not only to determine whether the eﬀects exerted
by PPARα ligand are indeed PPARα-dependent, but also
for discerning between host versus tumor-mediated PPARα
responses (see Table 2 for details). In this regard, we have
shown that wild-type mice injected with isogenic PPARα
expressing tumor cells respond to WY14643 treatment and
develop fewer and smaller tumors than untreated wild-type
mice [38]. In contrast, the growth of the same tumor cells isA. Pozzi and Jorge H. Capdevila 5
not prevented in WY14643-treated PPARα null mice [38]. In
agreement with our ﬁnding, absence of PPARα in the host
animals abrogated the potent antitumor eﬀect of fenoﬁbrate
[48]. Finally whereas in vivo activation of PPARα prevents
vascular smooth muscle cell proliferation underlying intimal
hyperplasia, PPARα deﬁciency leads to hyperplasia [56].
Taken together, these results strongly suggest that activation
ofPPARαinthehostisakeyelementinpreventingunwanted
pathological cell growth.
Although rodents are the only species in which acti-
vation of PPARα promotes liver cancer, for a long time
it was thought that Di(2-ethylhexyl)phthalate (DEHP), a
commonly used industrial plasticizer, might cause liver
tumorigenesis presumably via activation of PPARα [55, 71].
The use of PPARα null mice has disproved this idea, as
this plasticizer is able to induce tumorigenesis in both
wild-type and PPARα-null mice [55, 71]. These results
suggest the existence of pathways for DEHP-induced hepatic
tumorigenesis that are independent of PPARα,b u tm o s t
likely dependent on DEHP-mediated oxidative stress [55].
PPARα null mice have been also instrumental to deter-
mine the role of rodent versus human PPARα in the promo-
tion of liver carcinogenesis. Morimura et al. have generated
aP P A R α-humanized mouse in which the human PPARα
is expressed in liver under control of the Tet-OFF system.
Interestingly, prolonged exposure to WY14643 in these mice
only led to a 5% incidence of liver tumors—including
hepatocellular carcinoma—compared to the 71% observed
in mice expressing the mouse PPARα [53]. More recently,
Yanget al. generated a PPARα-humanized transgenic mouse
wherethecompletehumanPPARαgenewasintroducedonto
aP P A R α-null background [54]. These PPARα-humanized
mice express the human PPARα in liver as well as other tis-
sues and respond to fenoﬁbrate treatment by lowering serum
triglycerides and by inducing the expression of enzymes
involved in fatty acid metabolism [54]. However, in contrast
to wild-type mice, treatment with fenoﬁbrate did not cause
signiﬁcant hepatomegaly, hepatocyte proliferation, and most
importantly hepatocarcinoma [54]. Thus, this study shows
that the protumorigenic let-7C/c-myc pathway is activated
onlybytherodent,butnotthehumanPPARαreceptor. Most
importantly, this work highlights the possibility that PPARα
ligands might be used as safe drugs for the treatment of
cancer in humans.
Although activation of PPARα in either endothelial or
tumor cells has been proven to be beneﬁcial in inhibiting
cancer growth, it has also been shown that loss of host-
derived PPARα c a nb ea d v a n t a g e o u sa si tp r e v e n t st u m o r
growth and development [57]. The host cells responsible
for this protection, however, are granulocytes rather than
endothelial cells. Loss of PPARα leads to an increased
inﬁltration to the side of injury of granulocytes that suppress
tumor-associated angiogenesis via excess production of the
endogenous angiogenesis inhibitor thrombospondin [57].
This study clearly indicates that both activation of PPARα
in speciﬁc host cells (i.e., endothelia cells) and concomitant
inhibition of PPARα in immuno cells (i.e., granulocytes)
might lead to the same eﬀects, namely protection from
tumor growth.
6. CONCLUSIONS
The studies summarized in this review identify PPARα as
a potential host-based target for the development of new
antiangiogenic approaches to inhibit and/or prevent tumor
growth. As an established modulator of gene transcription,
PPARα regulates the expression of genes known to be
involved in energy metabolism, cellular proliferation, and
angiogenesis and to have positive eﬀects on the control
of dyslipidemia, inﬂammation, and cardiovascular diseases.
Furthermore, several ﬁbric acid derivatives bind to and
activate human PPARα with limited or no documented
unwanted consequences and have proven to be safe and
eﬀective hypolipidemic drugs. In this context, gemﬁbrozil
safely reduced the risk of death from coronary heart disease,
nonfatal myocardial infarction, or stroke by raising HDL
cholesterol levels and lowering levels of triglycerides [72, 73].
The eﬀects of PPARα ligands in animal models of tumor
angiogenesis should help not only to stimulate further
research of their usefulness as antitumorigenic agents, but
also to facilitate their evaluation as valid tools for the
treatment and/or prevention of human cancers. In this
context, it is our hope that these studies will serve to
encourage epidemiological studies of cancer incidence in
patientsusinghypolipidemicdrugs,andhelptoidentifytheir
potential beneﬁcial eﬀects as agents for tumor prevention
and/or treatment. The urgency of new approaches for cancer
treatment are indicated by the fact that most current antitu-
morigenictherapiesareorientedtowardsageneralinhibition
of tumor cell growth and, as such, they suﬀer from lacking
target selectivity and, in most cases, causing severe side
eﬀects and overall systemic toxicity. Thus, targeting PPARα
may prove to be a potential therapeutic strategy—either
alone or in combination with conventional chemotherapy—
to inhibit and ideally prevent cancer with excellent tolerance
and limited toxicity.
ACKNOWLEDGMENT
This work was supported in part by DK074359 (AP),
GM37922 (JHC), and DK38226 (JHC).
REFERENCES
[1] S. Kersten, B. Desvergne, and W. Wahli, “Roles of PPARS in
health and disease,” Nature, vol. 405, no. 6785, pp. 421–424,
2000.
[2] S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and
R. M. Evans, “Convergence of 9-cis retinoic acid and perox-
isome proliferator signalling pathways through heterodimer
formation of their receptors,” Nature, vol. 358, no. 6389, pp.
771–774, 1992.
[3] A. Aranda and A. Pascual, “Nuclear hormone receptors and
gene expression,” Physiological Reviews,v o l .8 1 ,n o .3 ,p p .
1269–1304, 2001.
[4] B. Desvergne and W. Wahli, “Peroxisome proliferator-
activated receptors: nuclear control of metabolism,” Endocrine
Reviews, vol. 20, no. 5, pp. 649–688, 1999.
[5] R. K. Semple, V. K. K. Chatterjee, and S. O’Rahilly, “PPARγ
and human metabolic disease,” Journal of Clinical Investiga-
tion, vol. 116, no. 3, pp. 581–589, 2006.6 PPAR Research
[6] P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation
of adipogenesis in ﬁbroblasts by PPARγ2, a lipid-activated
transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994.
[7] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K.
Glass, “The peroxisome proliferator-activated receptor-γ is a
negativeregulatorofmacrophageactivation,”Nature,vol.391,
no. 6662, pp. 79–82, 1998.
[8] N. Kubota, Y. Terauchi, H. Miki, et al., “PPARγ mediates
high-fat diet-induced adipocyte hypertrophy and insulin
resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999.
[9] S. Schwartz, P. Raskin, V. Fonseca, and J. F. Graveline, “Eﬀect
of troglitazone in insulin-treated patients with type II diabetes
mellitus,” The New England Journal of Medicine, vol. 338, no.
13, pp. 861–866, 1998.
[10] S. A. Kliewer, B. M. Forman, B. Blumberg, et al., “Diﬀerential
expression and activation of a family of murine peroxisome
proliferator-activated receptors,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 91, no.
15, pp. 7355–7359, 1994.
[ 1 1 ]O .B r a i s s a n t ,F .F o u f e l l e ,C .S c o t t o ,M .D a u c ¸a, and W. Wahli,
“Diﬀerential expression of peroxisome proliferator-activated
receptors (PPARs): tissue distribution of PPAR-α,- β, and -γ
in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366,
1996.
[12] G. Rizzo and S. Fiorucci, “PPARs and other nuclear receptors
ininﬂammation,”CurrentOpinioninPharmacology,vol.6,no.
4, pp. 421–427, 2006.
[13] R. M. Touyz and E. L. Schiﬀrin, “Peroxisome proliferator-
activatedreceptorsinvascularbiology-molecularmechanisms
and clinical implications,” Vascular Pharmacology, vol. 45, no.
1, pp. 19–28, 2006.
[14] S. Z. Duan, M. G. Usher, and R. M. Mortensen, “Peroxisome
proliferator-activated receptor-γ-mediated eﬀects in the vas-
culature,” Circulation Research, vol. 102, no. 3, pp. 283–294,
2008.
[15] S. Theocharis, A. Margeli, P. Vielh, and G. Kouraklis, “Per-
oxisome proliferator-activated receptor-γ ligands as cell-cycle
modulators,” Cancer Treatment Reviews, vol. 30, no. 6, pp.
545–554, 2004.
[16] R. A. Roberts, S. Chevalier, S. C. Hasmall, N. H. James, S. C.
Cosulich, and N. Macdonald, “PPARα and the regulation of
cell division and apoptosis,” Toxicology, vol. 181-182, pp. 167–
170, 2002.
[17] C. Giaginis, A. Tsantili-Kakoulidou, and S. Theocharis, “Per-
oxisome proliferator-activated receptor-γ ligands: potential
pharmacological agents for targeting the angiogenesis signal-
ing cascade in cancer,” PPAR Research, vol. 2008, Article ID
431763, 12 pages, 2008.
[18] Y. Yasui, M. Kim, and T. Tanaka, “PPAR ligands for cancer
chemoprevention,” PPAR Research, vol. 2008, Article ID
548919, 10 pages, 2008.
[19] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-
proliferator-activated receptors and cancers: complex stories,”
Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004.
[20] J.-S. Annicotte, I. Iankova, S. Miard, et al., “Peroxisome
proliferator-activated receptor γ regulates E-cadherin expres-
sion and inhibits growth and invasion of prostate cancer,”
Molecular and Cellular Biology, vol. 26, no. 20, pp. 7561–7574,
2006.
[21] M. Li, T. W. Lee, A. P. C. Yim, T. S. K. Mok, and G. G.
Chen, “Apoptosis induced by troglitazone is both peroxi-
some proliterator-activated receptor-γ- and ERK-dependent
in human non-small lung cancer cells,” Journal of Cellular
Physiology, vol. 209, no. 2, pp. 428–438, 2006.
[22] X. Xin, S. Yang, J. Kowalski, and M. E. Gerritsen, “Peroxisome
proliferator-activated receptor γ ligands are potent inhibitors
of angiogenesis in vitro and in vivo,” Journal of Biological
Chemistry, vol. 274, no. 13, pp. 9116–9121, 1999.
[23] M. Meissner, M. Stein, C. Urbich, et al., “PPARα activa-
tors inhibit vascular endothelial growth factor receptor-2
expression by repressing Sp1-dependent DNA binding and
transactivation,” Circulation Research, vol. 94, no. 3, pp. 324–
332, 2004.
[24] S. Goetze, F. Eilers, A. Bungenstock, et al., “PPAR activators
inhibit endothelial cell migration by targeting Akt,” Biochem-
ical and Biophysical Research Communications, vol. 293, no. 5,
pp. 1431–1437, 2002.
[25] J. Varet, L. Vincent, P. Mirshahi, et al., “Fenoﬁbrate inhibits
angiogenesis in vitro and in vivo,” Cellular and Molecular Life
Sciences, vol. 60, no. 4, pp. 810–819, 2003.
[26] C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C.
Glineur, “Peroxisome proliferator-activated receptors: regula-
tion of transcriptional activities and roles in inﬂammation,”
The Journal of Steroid Biochemistry and Molecular Biology, vol.
85, no. 2–5, pp. 267–273, 2003.
[27] N. Niho, M. Takahashi, T. Kitamura, et al., “Concomitant
suppression of hyperlipidemia and intestinal polyp formation
in Apc-deﬁcient mice by peroxisome proliferator-activated
receptor ligands,” Cancer Research, vol. 63, no. 18, pp. 6090–
6095, 2003.
[28] C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier,
“Intestinal-speciﬁc PPARγ deﬁciency enhances tumorigenesis
in Apc
Min/+ mice,” InternationalJournalofCancer, vol. 119, no.
10, pp. 2339–2346, 2006.
[29] A.-M. Lefebvre, I. Chen, P. Desreumaux, et al., “Activation of
t h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o rγ promotes the
development of colon tumors in C57BL/6J-Apc
Min/+ mice,”
Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998.
[30] Y. Guan, C. Hao, D. R. Cha, et al., “Thiazolidinediones expand
body ﬂuid volume through PPARγ stimulation of ENaC-
mediated renal salt absorption,” Nature Medicine, vol. 11, no.
8, pp. 861–866, 2005.
[31] D. Wang, H. Wang, Y. Guo, et al., “Crosstalk between perox-
isome proliferator-activated receptor δ a n dV E G Fs t i m u l a t e s
cancer progression,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 103, no. 50, pp.
19069–19074, 2006.
[32] H. E. Marin, M. A. Peraza, A. N. Billin, et al., “Ligand
activation of peroxisome proliferator-activated receptor β
inhibits colon carcinogenesis,” Cancer Research, vol. 66, no. 8,
pp. 4394–4401, 2006.
[33] F. J. Gonzalez and Y. M. Shah, “PPARα: mechanism of
species diﬀerences and hepatocarcinogenesis of peroxisome
proliferators,” Toxicology, vol. 246, no. 1, pp. 2–8, 2008.
[34] J. M. Peters, C. Cheung, and F. J. Gonzalez, “Peroxisome
proliferator-activatedreceptor-αandlivercancer:wheredowe
stand?” Journal of Molecular Medicine, vol. 83, no. 10, pp. 774–
785, 2005.
[35] J. C. Corton, P. J. Lapinskas, and F. J. Gonzalez, “Central role
of PPARα in the mechanism of action of hepatocarcinogenic
peroxisome proliferators,” Mutation Research, vol. 448, no. 2,
pp. 139–151, 2000.
[36] A. D. Blann, F. M. Belgore, J. Constans, C. Conri, and
G. Y. H. Lip, “Plasma vascular endothelial growth factor
and its receptor Flt-1 in patients with hyperlipidemia and
atherosclerosis and the eﬀectsofﬂuvastatinorfenoﬁbrate,” The
American Journal of Cardiology, vol. 87, no. 10, pp. 1160–1163,
2001.A. Pozzi and Jorge H. Capdevila 7
[37] F. Biscetti, E. Gaetani, A. Flex, et al., “Selective activation
of peroxisome proliferator-activated receptor (PPAR)α and
PPARγ induces neoangiogenesis through a vascular endothe-
lial growth factor-dependent mechanism,” Diabetes, vol. 57,
no. 5, pp. 1394–1404, 2008.
[38] A. Pozzi, M. R. Ibanez, A. E. Gatica, et al., “Peroxiso-
mal proliferator-activated receptor-α-dependent inhibition of
endothelial cell proliferation and tumorigenesis,” Journal of
Biological Chemistry, vol. 282, no. 24, pp. 17685–17695, 2007.
[39] A. Pozzi, I. Macias-Perez, T. Abair, et al., “Characterization
of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET)
as potent in vivo angiogenic lipids,” Journal of Biological
Chemistry, vol. 280, no. 29, pp. 27138–27146, 2005.
[40] U. R. Michaelis and I. Fleming, “From endothelium-derived
hyperpolarizing factor (EDHF) to angiogenesis: epoxye-
icosatrienoic acids (EETs) and cell signaling,” Pharmacology
&amp; Therapeutics, vol. 111, no. 3, pp. 584–595, 2006.
[41] I. Fleming, “Epoxyeicosatrienoic acids, cell signaling and
angiogenesis,” Prostaglandins &amp; Other Lipid Mediators,
vol. 82, no. 1–4, pp. 60–67, 2007.
[42] J. H. Capdevila, J. R. Falck, and R. C. Harris, “Cytochrome
P450 and arachidonic acid bioactivation: molecular and
functional properties of the arachidonate monooxygenase,”
Journal of Lipid Research, vol. 41, no. 2, pp. 163–181, 2000.
[43] J. H. Capdevila, J. R. Falck, E. Dishman, and A. Karara,
“Cytochrome P-450 arachidonate oxygenase,” Methods in
Enzymology, vol. 187, pp. 385–394, 1990.
[44] M. Potente, U. R. Michaelis, B. Fisslthaler, R. Busse, and
I. Fleming, “Cytochrome P450 2C9-induced endothelial cell
proliferation involves induction of mitogen-activated protein
(MAP) kinase phosphatase-1, inhibition of the c-Jun N-
terminal kinase, and up-regulation of cyclin D1,” Journal of
Biological Chemistry, vol. 277, no. 18, pp. 15671–15676, 2002.
[45] M. Potente, B. Fisslthaler, R. Busse, and I. Fleming, “11,12-
epoxyeicosatrienoic acid-induced inhibition of FOXO fac-
tors promotes endothelial proliferation by down-regulating
p27
Kip1,” Journal of Biological Chemistry, vol. 278, no. 32, pp.
29619–29625, 2003.
[ 4 6 ]U .R .M i c h a e l i s ,J .R .F a l c k ,R .S c h m i d t ,R .B u s s e ,a n dI .
Fleming, “Cytochrome P4502C9-derived epoxyeicosatrienoic
acids induce the expression of cyclooxygenase-2 in endothelial
cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
25, no. 2, pp. 321–326, 2005.
[47] U. R. Michaelis, B. Fisslthaler, M. Medhora, D. Harder,
I. Fleming, and R. Busse, “Cytochrome P450 2C9-derived
epoxyeicosatrienoic acids induce angiogenesis via cross-talk
with the epidermal growth factor receptor (EGFR),” The
FASEB Journal, vol. 17, no. 6, pp. 770–772, 2003.
[48] D. Panigrahy, A. Kaipainen, S. Huang, et al., “PPARα agonist
fenoﬁbrate suppresses tumor growth through direct and
indirect angiogenesis inhibition,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 105,
no. 3, pp. 985–990, 2008.
[49] Y. Yokoyama, B. Xin, T. Shigeto, et al., “Cloﬁbric acid, a perox-
isome proliferator-activated receptor α ligand, inhibits growth
of human ovarian cancer,” Molecular Cancer Therapeutics, vol.
6, no. 4, pp. 1379–1386, 2007.
[50] L. Jackson, W. Wahli, L. Michalik, et al., “Potential role
for peroxisome proliferator activated receptor (PPAR) in
preventing colon cancer,” Gut, vol. 52, no. 9, pp. 1317–1322,
2003.
[51] N. Niho, M. Mutoh, M. Takahashi, K. Tsutsumi, T. Sugimura,
and K. Wakabayashi, “Concurrent suppression of hyperlipi-
demia and intestinal polyp formation by NO-1886, increasing
lipoprotein lipase activity in Min mice,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 102, no. 8, pp. 2970–2974, 2005.
[52] Y. M. Shah, K. Morimura, Q. Yang, T. Tanabe, M. Takagi, and
F. J. Gonzalez, “Peroxisome proliferator-activated receptor α
regulates a microRNA-mediated signaling cascade responsible
for hepatocellular proliferation,” Molecular and Cellular Biol-
ogy, vol. 27, no. 12, pp. 4238–4247, 2007.
[ 5 3 ]K .M o r i m u r a ,C .C h e u n g ,J .M .W a r d ,J .K .R e d d y ,a n dF .J .
Gonzalez, “Diﬀerential susceptibility of mice humanized for
peroxisome proliferator-activated receptor α to Wy-14,643-
induced liver tumorigenesis,” Carcinogenesis,v o l .2 7 ,n o .5 ,p p .
1074–1080, 2006.
[54] Q. Yang, T. Nagano, Y. Shah, C. Cheung, S. Ito, and F.
J. Gonzalez, “The PPARα-humanized mouse: a model to
investigate species diﬀerences in liver toxicity mediated by
PPARα,” Toxicological Sciences, vol. 101, no. 1, pp. 132–139,
2008.
[55] Y. Ito, O. Yamanoshita, N. Asaeda, et al., “Di(2-
ethylhexyl)phthalate induces hepatic tumorigenesis through
a peroxisome proliferator-activated receptor α-independent
pathway,” Journal of Occupational Health,v o l .4 9 ,n o .3 ,p p .
172–182, 2007.
[ 5 6 ]F .G i z a r d ,C .A m a n t ,O .B a r b i e r ,e ta l . ,“ P P A R α inhibits
vascular smooth muscle cell proliferation underlying intimal
hyperplasia by inducing the tumor suppressor p16
INK4a,” The
Journal of Clinical Investigation, vol. 115, no. 11, pp. 3228–
3238, 2005.
[57] A. Kaipainen, M. W. Kieran, S. Huang, et al., “PPARα
deﬁciency in inﬂammatory cells suppresses tumor growth,”
PLoS ONE, vol. 2, no. 2, p. e260, 2007.
[58] P. Howroyd, C. Swanson, C. Dunn, R. C. Cattley, and J.
C. Corton, “Decreased longevity and enhancement of age-
dependent lesions in mice lacking the nuclear receptor perox-
isome proliferator-activated receptor α (PPARα),” Toxicologic
Pathology, vol. 32, no. 5, pp. 591–599, 2004.
[59] G. P. Collett, A. M. Betts, M. I. Johnson, et al., “Peroxisome
proliferator-activated receptor α is an androgen-responsive
gene in human prostate and is highly expressed in prostatic
adenocarcinoma,” Clinical Cancer Research,v o l .6 ,n o .8 ,p p .
3241–3248, 2000.
[ 6 0 ]K .M .S u c h a n e k ,F .J .M a y ,J .A .R o b i n s o n ,e ta l . ,“ P e r o x i s o m e
proliferator-activated receptor α in the human breast cancer
cell lines MCF-7 and MDA-MB-231,” Molecular Carcinogene-
sis, vol. 34, no. 4, pp. 165–171, 2002.
[ 6 1 ]K .M .S u c h a n e k ,F .J .M a y ,W .J .L e e ,N .A .H o l m a n ,a n d
S. J. Roberts-Thomson, “Peroxisome proliferator-activated
receptor β expression in human breast epithelial cell lines of
tumorigenic and non-tumorigenic origin,” The International
Journal of Biochemistry &amp; Cell Biology, vol. 34, no. 9, pp.
1051–1058, 2002.
[62] T. Tanaka, H. Kohno, S.-I. Yoshitani, et al., “Ligands for
peroxisome proliferator-activated receptors α and γ inhibit
chemically induced colitis and formation of aberrant crypt
foci in rats,” Cancer Research, vol. 61, no. 6, pp. 2424–2428,
2001.
[63] G. Muzio, M. Maggiora, M. Oraldi, A. Trombetta, and R. A.
Canuto, “PPARα and PP2A are involved in the proapoptotic
eﬀect of conjugated linoleic acid on human hepatoma cell line
SK-HEP-1,” International Journal of Cancer, vol. 121, no. 11,
pp. 2395–2401, 2007.
[ 6 4 ]M .M a g g i o r a ,M .B o l o g n a ,M .P .C e r ` u, et al., “An overview
of the eﬀect of linoleic and conjugated-linoleic acids on8 PPAR Research
the growth of several human tumor cell lines,” International
Journal of Cancer, vol. 112, no. 6, pp. 909–919, 2004.
[65] S. A. Saidi, C. M. Holland, D. S. Charnock-Jones, and S. K.
Smith, “In vitro and in vivo eﬀects of the PPAR-alpha agonists
fenoﬁbrateandretinoicacidinendometrialcancer,”Molecular
Cancer, vol. 5, article 13, 2006.
[66] P. Thuillier, G. J. Anchiraico, K. P. Nickel, et al., “Activators of
peroxisome proliferator-activated receptor-α partially inhibit
mouse skin tumor promotion,” Molecular Carcinogenesis, vol.
29, no. 3, pp. 134–142, 2000.
[67] M. Grabacka, P. M. Plonka, K. Urbanska, and K. Reiss, “Per-
oxisome proliferator-activated receptor α activation decreases
metastatic potential of melanoma cells in vitro via down-
regulation of Akt,” Clinical Cancer Research, vol. 12, no. 10,
pp. 3028–3036, 2006.
[68] M. Grabacka, W. Placha, P. M. Plonka, et al., “Inhibition of
melanoma metastases by fenoﬁbrate,” Archives of Dermatolog-
ical Research, vol. 296, no. 2, pp. 54–58, 2004.
[69] T. Hays, I. Rusyn, A. M. Burns, et al., “Role of peroxisome
proliferator-activated receptor-α (PPARα) in bezaﬁbrate-
induced hepatocarcinogenesis and cholestasis,” Carcinogene-
sis, vol. 26, no. 1, pp. 219–227, 2005.
[70] F. J. Gonzalez, “The peroxisome proliferator-activated recep-
tor α (PPARα): role in hepatocarcinogenesis,” Molecular and
Cellular Endocrinology, vol. 193, no. 1-2, pp. 71–79, 2002.
[71] K. Takashima, Y. Ito, F. J. Gonzalez, and T. Nakajima, “Dif-
ferent mechanisms of DEHP-induced hepatocellular adenoma
tumorigenesis in wild-type and Pparα-null mice,” Journal of
Occupational Health, vol. 50, no. 2, pp. 169–180, 2008.
[72] H. B. Rubins, S. J. Robins, D. Collins, et al., “Gemﬁbrozil for
the secondary prevention of coronary heart disease in men
with low levels of high-density lipoprotein cholesterol,” The
New England Journal of Medicine, vol. 341, no. 6, pp. 410–418,
1999.
[73] M. H. Frick, O. Elo, K. Haapa, et al., “Helsinki Heart Study:
primary-prevention trial with gemﬁbrozil in middle-aged
men with dyslipidemia. Safety of treatment, changes in risk
factors, and incidence of coronary heart disease,” The New
England Journal of Medicine, vol. 317, no. 20, pp. 1237–1245,
1987.